Today, Akero announced the initiation of SYNCHRONY Outcomes, the third study in our Phase 3 SYNCHRONY trial program. We are actively recruiting patients with compensated cirrhosis, fibrosis stage 4 (F4) due to #MASH to take part in this global, randomized, placebo-controlled, 2-cohort, Phase 3 trial evaluating the efficacy and safety of #EFX. Read more here: https://lnkd.in/egxvSuz7 #ClinicalTrials
👍
Congratulations to the Akero team!
Great stuff Kitty! 😀
Very exciting Kitty!
Congrats Kitty
Chief of Hepatology / Executive Director of Research (Transplant)
2moGive us a call at the Lahey ! We have a significant number of these patients